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Abstract 
Herein we describe the case of a 64-year old
man with a history of mantle cell lymphoma
found to have evidence of pulmonary parenchy-
mal  involvement  by  recurrence  of  his  lym-
phoma. While lung involvement is not neces-
sarily  uncommon  with  Non-Hodgkin’s  lym-
phomas as a group, it is very rare for mantle
cell lymphoma to involve the lung parenchyma.
In addition, the radiographic manifestation of
his pulmonary lymphoma as a discrete FDG-
avid ground-glass lesion on chest imaging was
also distinctly uncommon for pulmonary lym-
phoma  which  classically  appears  in  one  of
three patterns: scattered ill-defined nodules, a
bronchovascular/lymphangitic  process,  or
pneumonic/alveolar  consolidation  effectively
indistinguishable  from  bacterial  pneumonia.
Due to significant underlying lung disease our
patient was not a candidate for high-dose con-
ditioning and autologous stem cell transplanta-
tion. He was ultimately treated with rituximab
and cladribine therapy and had early signs of
clinical response at last correspondence.
Case Report
A  64-year-old  man  with  a  history  of  Non-
Hodgkin’s lymphoma (NHL) was referred for
evaluation of dyspnea and an indeterminate
lung lesion. Two years prior to presentation he
was diagnosed with mantle cell lymphoma by
bone  marrow  biopsy  demonstrating  B-cells
with  consistent  flow  markings  and  11;14
translocation by fluorescent in-situ hybridiza-
tion  (FISH)  analysis.  He  was  subsequently
treated with 6 cycles of rituximab, cyclophos-
phamide,  doxorubicin,  vincristine  and  pred-
nisone (R-CHOP) and achieved remission by
positron  emission  tomography  -  computed
tomography (PET/CT) imaging and bone mar-
row biopsy. He was evaluated for autologous
stem cell transplant but this was deferred due
to limited pulmonary reserve. He was treated
with  rituximab  maintenance  therapy  until  a
follow-up  PET/CT  showed  concern  for  recur-
rence at which point he was treated with 6
cycles of bendamustine, bortezomib, and ritux-
imab. Repeat PET/CT imaging again showed
persistence  of  FDG-avid  lymphadenopathy
within his neck, chest, abdomen, and pelvis, as
well as a ground-glass opacity in the left lung
for which he was referred for pulmonary con-
sultation. 
During  the  pulmonary  consultation  the
patient noted that he had dyspnea on exertion
to the point of limiting his ability to walk more
than one block without resting. This was chron-
ic and related to his history of chronic obstruc-
tive pulmonary disease. Other than lower back
pain and a mild non-productive cough, the rest
of his review of symptoms was negative. He
specifically denied weight loss, night sweats,
fevers, chills, myalgias, and hemoptysis.
Vital  signs  were  as  follows:  temperature
35.6ºC; heart rate 94/min; BP 139/78 mmHg,
respirations 16/min; BMI 26.4 Kg/m2. Pertinent
findings on physical exam included a small pal-
pable  lymph  node  in  the  left  submandibular
region and mild fine bibasilar crackles on lung
exam without wheezing. The remainder of the
exam was unremarkable.
Laboratory studies including complete blood
count with differential cell count, electrolytes,
renal and liver function tests were all within
normal  limits.  Pulmonary  function  testing
revealed  mild  irreversible  obstruction  with
normal lung volumes. The diffusing capacity
was reduced and there was oxygen desatura-
tion with minimal activity. A high resolution
computed  tomography  scan  of  the  chest
(Figure 1A) showed an isolated area of ground-
glass opacification in the left lower lobe which
was  highly  FDG-avid  on  positron  emission
tomography  (Figure  1B).  Flexible  bron-
choscopy with broncho-alveolar lavage of the
left lateral basal segment was performed. The
effluent was sent for microbiologic analysis for
routine  and  opportunistic  pathogens.  All
microbiologic data was ultimately unrevealing.
Iron  stain  was  performed  and  showed  no
hemosiderin-laden  macrophages.  Cytologic
evaluation showed no evidence of malignancy.
Transthoracic  fine  needle  aspiration  of  the
lesion was ultimately performed and showed
an atypical population of CD-20 positive B-cells
(Figure  2A)  coexpressing  CD-5,  blc-2,  and
cyclin  D1  (Figure  2B)  consistent  with  pul-
monary mantle cell lymphoma.
After confirmation of relapse of his mantle
cell  lymphoma  the  patient  returned  to  his
hematologist  to  discuss  therapeutic  options.
Unfortunately,  due  to  his  underlying  pul-
monary disease he was not felt to be a candi-
date  for  high-dose  conditioning  and  autolo-
gous  stem  cell  transplant.  The  decision  was
made for the patient to proceed with rituximab
and cladribine therapy. Review of recent corre-
spondence from his local providers indicates
he is tolerating chemotherapy well with early
signs of clinical response.
Discussion
Pulmonary infiltrates in immunosuppressed
patients are frequently encountered given the
increased use of immunosuppressive chemo  -
therapeutics  and  transplant  procedures  per-
formed over the past few decades. Infectious
etiologies are certainly the foremost concern in
immunosuppressed  patients  presenting  with
respiratory symptoms and new pulmonary infil-
trates on chest imaging. Flexible bronchoscopy
with  bronchoalveolar  lavage  is  frequently
employed as a diagnostic tool in the evaluation
of these patients. Bronchoalveolar lavage of the
affected region allows for multiple microbiolog-
ic diagnostic studies including varied stains,
cultures,  and  genetic  studies  for  bacteria,
mycobacteria,  fungi,  and  viruses,  as  well  as
cytologic evaluations for malignancy and dif-
fuse  alveolar  hemorrhage.  While  infectious
processes represent a significant portion of the
pulmonary infiltrates in immunocompromised
patients, non-infectious etiologies must also be
considered. 
Parenchymal  lung  involvement  in  Non-
Hodgkin’s lymphoma (NHL) is uncommon and
is reported to be present in less than 5% of
patients at the time of diagnosis. It is impor-
tant to note, however, that the prevalence of
parenchymal lung involvement increases over
time and may be present in as many as 24% of
patients during their disease course. This is in
contrast  to  Hodgkin’s  lymphoma  in  which
nearly 10% of patients have lung involvement
at  presentation  and  35-40%  will  develop
parenchymal  disease  during  their  disease
course.1 Interestingly,  lung  parenchymal
involvement in NHL frequently occurs in the
absence of significant thoracic adenopathy. As
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with all other features of NHL, the prevalence
of lung involvement is highly dependent on the
specific pathologic cell type. 
Radiographic  features  of  pulmonary  lym-
phoma on chest CT imaging are varied but clas-
sically present in one of three patterns. The
most common appearance is that of scattered
ill-defined  nodules  with  lower  lobe  predomi-
nance. These nodules frequently include air-
bronchograms; cavitations with or without air
fluid levels are also possible. The second most
common pattern is a bronchovascular/lymphan-
gitic process with coarse linear and reticulon-
odular shadows extending outwards from the
hilum in a perivascular and peribronchial dis-
tribution.  When  extensive  this  pattern  can
appear very similar to consolidative bronchop-
neumonia.  The  third  pattern  is  described  as
pneumonic/alveolar and is effectively indistin-
guishable from bacterial pneumonia. It can be
a segmental or lobar process. The only discern-
ing feature is an absence of volume loss which
would  be  consistent  with  a  consolidative
process.2 Ground-glass opacification is a dis-
tinctly uncommon presentation of pulmonary
lymphoma and not classically described.
Mantle cell lymphoma (MCL) is a mature
B-cell NHL characterized by proliferation of B-
cells resembling those found in the follicular
mantle zones and accounts for approximately
5% of NHL. It is most often a very aggressive
disease  typically  presenting  in  the  sixth
decade with a male predominance.3,4 Cyclin
D1 nuclear staining is positive in over 90% of
cases.  Cyclin  D1  overexpression  is  strongly
associated  with  the  t(11;14),  however  this
translocation is present by karyotyping in only
50%-65% of patients.5 The majority of patients
with MCL present with advanced disease with
over  75%  of  patients  having  extranodal
involvement at presentation. The most com-
mon sites of extranodal involvement include
the bone marrow, peripheral blood, GI tract,
Waldeyer’s  ring,  and  liver  in  descending
order. In one study 25% of patients with MCL
had an extranodal site as the primary site of
involvement at presentation, though none of
these  patients  had  parenchymal  lung  dis-
ease.3 Despite  the  frequency  of  extranodal
disease in MCL it is still distinctly uncommon
for  the  lung  parenchyma  to  be  involved.
Nonetheless, the presence of a non-infectious
metabolically active infiltrate found on radi-
ographic chest imaging in any patient with
NHL, including MCL, should prompt efforts to
establish  a  tissue  diagnosis  of  pulmonary
lymphoma.
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Case Report
Figure 1. A) Non-contrast chest computed
tomograohy scan showing left lower lobe
ground-glass  opacification;  B)  chest
positron emission tomography - computed
tomography  image  demonstrating  FDG-
avidity of left lower lobe opacity.
Figure 2. Transthoracic needle aspiration
biopsy  specimens  from  left  lower  lobe
ground-glass  opacity,  original  magnifica-
tion ¥400, with hematoxylin-eosin (A) and
cyclin D1 (B) stains depicting an atypical
population of CD-20 positive B-cells coex-
pressing CD-5, blc-2, and cyclin D1.